When GPVI Goes Rogue: Pathogenesis and Therapeutic Horizons in ITP
Expert Reviews in Molecular Medicine · 2026 · 28
DOI: 10.1017/erm.2026.10047 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Reviews in Molecular Medicine, online erschienen am 13.04.2026. Verfasst von Jalal Naghinezhad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Sciences, School of Allied Medical Science, Mazandaran University of Medical Sciences, Sari, Iran. Hauptthemen laut MEDLINE: Platelet Membrane Glycoproteins, Purpura, Thrombocytopenic, Idiopathic, Blood Platelets. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disorder characterized by immune-mediated platelet destruction, impaired thrombopoiesis and a bleeding diathesis, with growing recognition of accompanying inflammatory and immunoregulatory disturbances. Despite the widespread use of corticosteroids, intravenous immunoglobulin (IVIG) and thrombopoietin receptor agonists (TPO-RAs), 30–50% of patients exhibit incomplete, unstable or transient platelet responses, underscoring a persistent unmet need for mechanism-informed therapeutic strategies. Current management paradigms remain largely focused on platelet count restoration rather than direct modulation of pathogenic platelet–immune crosstalk. Accumulating pre-clinical evidence, supported by limited clinical observations, implicates platelet glycoprotein VI (GPVI), a collagen receptor and immunothrombotic signalling hub, as a mechanistically relevant contributor to platelet hyperactivation, inflammatory amplification and aberrant platelet–leucocyte interactions in ITP. Experimental models indicate that GPVI-dependent signalling pathways can promote thromboinflammatory responses, facilitate immune cell engagement and influence platelet clearance dynamics, positioning GPVI as a plausible, albeit incompletely validated, therapeutic target. Emerging pre-clinical studies suggest that selective modulation of GPVI signalling may attenuate pathogenic platelet activation while preserving essential haemostatic function, thereby improving platelet survival and functional competence. This review integrates current insights into GPVI biology within the broader immunopathological landscape of ITP and evaluates innovative therapeutic concepts, including GPVI-targeted inhibitors deployed through nanocarrier systems, autologous platelet-mediated delivery and hydrogel-based protective platforms designed to enhance targeting precision and durability. We further discuss the rationale for combination strategies with established therapies and the potential utility of GPVI-linked biomarkers and platelet functional profiling to guide patient stratification. By reframing platelets as active immunoregulatory effectors rather than passive autoimmune targets, this review advances a mechanistic framework for next-generation, precision-oriented intervention in ITP. Although clinical validation remains limited, GPVI-centred strategies represent a rational and testable avenue for moving beyond symptomatic platelet augmentation towards disease-modifying immunothrombotic modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Laboratory Sciences, School of Allied Medical Science, Mazandaran University of Medical Sciences, Sari, Iran.
- Department of Emergency Medicine, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- School of Medicine, Jundishapur University of Medical Sciences, Ahvaz, Iran.
- Department of Internal Medicine, School of Medicine, Hazrat-e Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran.
- Laser Research Centre, University of Johannesburg, Doornfontein, South Africa.
- Asadabad School of Medical Sciences, Asadabad, Iran.
Zitieren
APA
Naghinezhad, J., Mohajerian, A., Ahadi, S., Khodakarim, N., Hamblin, M. R., & Rezaeeyan, H. (2026). When GPVI Goes Rogue: Pathogenesis and Therapeutic Horizons in ITP. Expert Reviews in Molecular Medicine, 28. https://doi.org/10.1017/erm.2026.10047
Vancouver
Naghinezhad J, Mohajerian A, Ahadi S, Khodakarim N, Hamblin MR, Rezaeeyan H. When GPVI Goes Rogue: Pathogenesis and Therapeutic Horizons in ITP. Expert Reviews in Molecular Medicine. 2026;28. doi:10.1017/erm.2026.10047
BibTeX
@article{Naghinezhad2026,
author = {Naghinezhad, Jalal and Mohajerian, Ahmad and Ahadi, Shana and Khodakarim, Nastaran and Hamblin, Michael R and Rezaeeyan, Hadi},
title = {When GPVI Goes Rogue: Pathogenesis and Therapeutic Horizons in ITP},
journal = {Expert Reviews in Molecular Medicine},
year = {2026},
volume = {28},
doi = {10.1017/erm.2026.10047}
}
EUVIMED